Regular Session
Government Affairs & Regulatory Compliance Analysis
Senate Bill 1044 mandates the addition of Duchenne muscular dystrophy (DMD) to the Texas Newborn Screening Panel for all birthing facilities and midwives. While the statutory effective date is September 1, 2025, operational implementation is strictly contingent upon legislative funding and the construction of new DSHS laboratory facilities, creating a projected 2-to-4-year delay before testing physically begins.
Sen. Tan Parker·Senate Bill·Regular Session
This legislation has regulatory implications for the following Texas businesses and organizations:
Notable regulatory updates (effective 2025-09-01). Consider how these changes may affect your operations.
Affected business types:
mediumModerate costs expected for implementation.
JD Key Consulting provides government affairs and regulatory strategy services. We help businesses navigate Texas agencies, understand legislative impacts, and advocate for their interests.
JD Key Consulting provides strategic guidance on Texas regulatory compliance and legislative impact for your business.
Key implementation requirements and action items for compliance with this legislation
JD Key Consulting specializes in Texas regulatory compliance strategy. Work directly with James Dickey—former Chairman of the Republican Party of Texas—to understand this bill's impact on your operations and develop an actionable compliance plan.
Schedule a ConsultationInformation presented is for general knowledge only and is provided without warranty, express or implied. Consult qualified government affairs professionals and legal counsel before making compliance decisions.
This bill's path through the Texas Legislature
Explore more bills from this author and on related topics
Common questions about SB1044
Senate Bill 1044 mandates the addition of Duchenne muscular dystrophy (DMD) to the Texas Newborn Screening Panel for all birthing facilities and midwives. While the statutory effective date is September 1, 2025, operational implementation is strictly contingent upon legislative funding and the construction of new DSHS laboratory facilities, creating a projected 2-to-4-year delay before testing physically begins.
SB1044 was authored by Texas Senator Tan Parker during the Regular Session.
SB1044 was signed into law by Governor Greg Abbott on May 19, 2025.
SB1044 is enforced by Department of State Health Services (DSHS).
The regulatory priority for SB1044 is rated as "moderate". Businesses and organizations should review the legislation to understand potential impacts.
The cost impact of SB1044 is estimated as "medium". This may vary based on industry and implementation requirements.
SB1044 addresses topics including health, health--general, health--other diseases & medical conditions, minors and minors--health & safety.
Key dates for SB1044: Effective date is 2025-09-01. Rulemaking: Implement Duchenne muscular dystrophy screening protocols and approve specific screening tests (Upon completion of laboratory facilities); Establish rules defining eligibility criteria for services for individuals with confirmed positive tests (Undefined). Consult with legal counsel regarding applicability.
SB1044 primarily affects healthcare providers and medical facilities. These businesses should review the legislation with their legal and compliance teams to understand potential impacts.
JD Key Consulting is an Austin, Texas-based government affairs firm led by James Dickey, former Chairman of the Republican Party of Texas. We specialize in Texas regulatory compliance and legislative strategy for data centers, energy, banking, and manufacturing.
